RGT 2.47% 41.5¢ argent biopharma limited

MGC Pharma (ASX:MXC) recruits first patient for phase III CimetrA trial

  1. 7,571 Posts.
    lightbulb Created with Sketch. 1047
    • MGC Pharma (MXC) recruits its first patient for the phase three CimetrA clinical trial in Israel
    • MXC is testing the treatment's safety and efficacy on patients with moderate forms of COVID-19
    • A total of 252 patients will take place in the trial which will provide additional data for CimetrA's Investigational Medicinal Product (IMP) status
    • MXC says the data from the trial should meet the European Medical Agency's qualification as well

    Read the Full Article on The Market Herald here
 
watchlist Created with Sketch. Add RGT (ASX) to my watchlist
(20min delay)
Last
41.5¢
Change
0.010(2.47%)
Mkt cap ! $18.79M
Open High Low Value Volume
41.0¢ 41.5¢ 41.0¢ $426 1.033K

Buyers (Bids)

No. Vol. Price($)
1 750 41.0¢
 

Sellers (Offers)

Price($) Vol. No.
41.5¢ 4467 1
View Market Depth
Last trade - 15.46pm 26/04/2024 (20 minute delay) ?
RGT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.